Controlling therapeutic protein expression via inhalation of a butter flavor molecule
Nucleic Acids Research · 2023
DOI: 10.1093/nar/gkac1256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2023. Verfasst von Adrian Bertschi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland. Hauptthemen laut MEDLINE: Acetoin, Diabetes Mellitus, Experimental, Transgenes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Swiss National Science Foundation, ETH Zürich.
Abstract (Originalsprache)
Precise control of the delivery of therapeutic proteins is critical for gene- and cell-based therapies, and expression should only be switched on in the presence of a specific trigger signal of appropriate magnitude. Focusing on the advantages of delivering the trigger by inhalation, we have developed a mammalian synthetic gene switch that enables regulation of transgene expression by exposure to the semi-volatile small molecule acetoin, a widely used, FDA-approved food flavor additive. The gene switch capitalizes on the bacterial regulatory protein AcoR fused to a mammalian transactivation domain, which binds to promoter regions with specific DNA sequences in the presence of acetoin and dose-dependently activates expression of downstream transgenes. Wild-type mice implanted with alginate-encapsulated cells transgenic for the acetoin gene switch showed a dose-dependent increase in blood levels of reporter protein in response to either administration of acetoin solution via oral gavage or longer exposure to acetoin aerosol generated by a commercial portable inhaler. Intake of typical acetoin-containing foods, such as butter, lychees and cheese, did not activate transgene expression. As a proof of concept, we show that blood glucose levels were normalized by acetoin aerosol inhalation in type-I diabetic mice implanted with acetoin-responsive insulin-producing cells. Delivery of trigger molecules using portable inhalers may facilitate regular administration of therapeutic proteins via next-generation cell-based therapies to treat chronic diseases for which frequent dosing is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland.
- Département Génie Biologique, Institut Universitaire de Technologie, Université Claude Bernard, Lyon 1 Villeurbanne Cedex F-69622, France.
- University of Basel, Faculty of Science, Mattenstrasse 26, CH-4058 Basel, Switzerland.
ORCID-Profile: Martin Fussenegger
Förderung
- European Research Council
- Swiss National Science Foundation
- ETH Zürich
Zitieren
APA
Bertschi, A., Stefanov, B. A., Xue, S., Charpin-El Hamri, G., Teixeira, A. P., & Fussenegger, M. (2023). Controlling therapeutic protein expression via inhalation of a butter flavor molecule. Nucleic Acids Research. https://doi.org/10.1093/nar/gkac1256
Vancouver
Bertschi A, Stefanov BA, Xue S, Charpin-El Hamri G, Teixeira AP, Fussenegger M. Controlling therapeutic protein expression via inhalation of a butter flavor molecule. Nucleic Acids Research. 2023. doi:10.1093/nar/gkac1256
BibTeX
@article{Bertschi2023,
author = {Bertschi, Adrian and Stefanov, Bozhidar-Adrian and Xue, Shuai and Charpin-El Hamri, Ghislaine and Teixeira, Ana Palma and Fussenegger, Martin},
title = {Controlling therapeutic protein expression via inhalation of a butter flavor molecule},
journal = {Nucleic Acids Research},
year = {2023},
doi = {10.1093/nar/gkac1256}
}
EUVIMED